Camrelizumab (anti-PD-1 inhibitor)

DRUG2 trials

Sponsors

Shanghai Jiao Tong University School of Medicine, Sun Yat-sen University

Conditions

Anti-PD-1Anti-VEGFRHepatocellulcar CarcinomaNeoadjvant TherapyOral Squamous Cell Carcinoma

Phase 2

Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients

RecruitingNCT05069857

Shanghai Jiao Tong University School of MedicineAnti-PD-1, Anti-VEGFR, Neoadjvant Therapy +1

Start: 2021-09-01End: 2028-06-30Target: 46Updated: 2023-11-22

Dalpiciclib Plus Camrelizumab for HCC Patients Who Have Previously Received ICI Treatment

RecruitingNCT07238881

Sun Yat-sen UniversityHepatocellulcar Carcinoma

Start: 2025-11-05End: 2027-06-01Target: 30Updated: 2025-11-20

Related Papers

A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma

Nature Communications2022-09-14110 citations